Hepion Pharmaceuticals logo

Hepion PharmaceuticalsNASDAQ: HEPA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 February 2014

Next earnings report:

21 May 2025

Last dividends:

N/A

Next dividends:

N/A
$4.83 M
-95%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-168%vs. 3y high
7%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Tue, 19 Nov 2024 21:00:00 GMT
$0.69+$0.07(+11.92%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

HEPA Latest News

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
globenewswire.com04 September 2024 Sentiment: POSITIVE

KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson's Disease (“PD”) and Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (“Hepion”), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today jointly announced the filing of a registration statement of Pharma Two B on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the “SEC”).

Hepion Pharmaceuticals to Present at NASH-TAG 2024
GlobeNewsWire03 January 2024 Sentiment: POSITIVE

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
GlobeNewsWire28 November 2023 Sentiment: POSITIVE

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat
GlobeNewsWire10 November 2023 Sentiment: POSITIVE

Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023 Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023

Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
GlobeNewsWire21 September 2023 Sentiment: POSITIVE

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Chief Executive Officer, Robert Foster, PharmD, PhD, will participate in a panel discussion during the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 9:45 a.m. ET in NYC.

Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
GlobeNewsWire15 June 2023 Sentiment: POSITIVE

- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution –

Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
Zacks Investment Research24 May 2023 Sentiment: POSITIVE

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.

HEPA stock price surged but beware of this glaring Hepion risk
Invezz23 May 2023 Sentiment: POSITIVE

Hepion Pharmaceuticals' (NASDAQ: HEPA) stock price went parabolic on Monday after the company made an important announcement about its mid-stage trial. The shares jumpd by more than 110% and reached a high of $19.66, the highest level since January 17.

Why Is Hepion Pharmaceuticals (HEPA) Stock Up 68% Today?
InvestorPlace22 May 2023 Sentiment: POSITIVE

Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is rising higher on Monday as the company prepares to cover clinical trial results. Hepion Pharmaceuticals is holding a conference call at 8:30 a.m.

Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat
GlobeNewsWire19 May 2023 Sentiment: POSITIVE

EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial before the market opens on Monday, May 22, 2023.

What type of business is Hepion Pharmaceuticals?

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

What sector is Hepion Pharmaceuticals in?

Hepion Pharmaceuticals is in the Healthcare sector

What industry is Hepion Pharmaceuticals in?

Hepion Pharmaceuticals is in the Biotechnology industry

What country is Hepion Pharmaceuticals from?

Hepion Pharmaceuticals is headquartered in United States

When did Hepion Pharmaceuticals go public?

Hepion Pharmaceuticals initial public offering (IPO) was on 10 February 2014

What is Hepion Pharmaceuticals website?

https://hepionpharma.com

Is Hepion Pharmaceuticals in the S&P 500?

No, Hepion Pharmaceuticals is not included in the S&P 500 index

Is Hepion Pharmaceuticals in the NASDAQ 100?

No, Hepion Pharmaceuticals is not included in the NASDAQ 100 index

Is Hepion Pharmaceuticals in the Dow Jones?

No, Hepion Pharmaceuticals is not included in the Dow Jones index

When was Hepion Pharmaceuticals the previous earnings report?

No data

When does Hepion Pharmaceuticals earnings report?

The next expected earnings date for Hepion Pharmaceuticals is 21 May 2025